Biogen (BIIB) Tops Q4 EPS by 57c, Offers Guidance
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $216.12 +3.04%
Revenue Growth %: -6.5%
Financial Fact:
Diluted earnings per share attributable to Biogen Idec Inc.: 219.4M
Today's EPS Names:
CRMT, More
Revenue Growth %: -6.5%
Financial Fact:
Diluted earnings per share attributable to Biogen Idec Inc.: 219.4M
Today's EPS Names:
CRMT, More
Join SI Premium – FREE
Biogen (NASDAQ: BIIB) reported Q4 EPS of $4.05, $0.57 better than the analyst estimate of $3.48. Revenue for the quarter came in at $2.54 billion versus the consensus estimate of $2.44 billion.
GUIDANCE:
Biogen sees FY2023 EPS of $15.00-$16.00, versus the consensus of $15.87.
- Mid-single digit revenue decline vs 2022
For earnings history and earnings-related data on Biogen (BIIB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Biogen expects $164M R&D charge to hit Q2 2026 earnings
- Greenbrier Cos. (GBX) Reports In-Line Q3 EPS
- Danone SA (BN:FP) (DANOY) PT Raised to EUR63 at Deutsche Bank
Create E-mail Alert Related Categories
Earnings, Guidance, Hot EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
